Home>>Signaling Pathways>> Stem Cell>> Notch>>RBPJ Inhibitor-1

RBPJ Inhibitor-1 (Synonyms: RIN1)

Catalog No.GC61233

RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation.

Products are for research use only. Not for human use. We do not sell to patients.

RBPJ Inhibitor-1 Chemical Structure

Cas No.: 2682114-39-0

Size Price Stock Qty
5mg
$93.00
In stock
10mg
$158.00
In stock
25mg
$324.00
In stock
50mg
$556.00
In stock
100mg
$908.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation[1].

RIN1 inhibits the proliferation of hematologic cancer cell lines and promoted skeletal muscle diferentiation from C2C12 myoblasts[1].RIN1 (0.6 µM, corresponding to 3 × IC50) decreases the number of MHC+ cells and increased the number of nuclei per cell, indicating that it induces the formation of multinucleated myofbers[1]. Cell Viability Assay[1] Cell Line: AD-293 cells were transfected with RBPJ-VP16myc.

[1]. Cecilia Hurtado, et al. Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ. Sci Rep. 2019 Jul 25;9(1):10811.

Reviews

Review for RBPJ Inhibitor-1

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for RBPJ Inhibitor-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.